Literature DB >> 31163438

Positive Association between Basal Total Testosterone Circulating Levels and Tumor Grade Groups at the Time of Diagnosis of Prostate Cancer.

Antonio B Porcaro1, Alessandro Tafuri2,3, Marco Sebben2, Marco Pirozzi2, Tania Processali2, Riccardo Rizzetto2, Nelia Amigoni2, Aliasger Shakir3, Leone Tiso2, Clara Cerrato2, Andrea Panunzio2, Mario De Michele2, Maria Angela Cerruto2, Matteo Brunelli4, Filippo Migliorini2, Salvatore Siracusano2, Walter Artibani2.   

Abstract

INTRODUCTION: To test the hypothesis that basal total testosterone (TT) levels are associated with International Society of Urologic Pathology (ISUP) tumor grade groups at the time of diagnosis of prostate cancer (PCA).
METHODS: From November 2014 to March 2018, preoperative TT and PSA were measured in 601 consecutive patients who were not under androgen deprivation and undergoing surgery for PCA. Patients were classified into low (ISUP 1; reference group), intermediate (ISUP 2/3), and high (ISUP 4/5) tumor grade groups. The association of TT and other clinical factors with tumor groups was evaluated by multinomial multivariate regression analysis.
RESULTS: 218 patients (36.3%) were biopsy low grade (ISUP 1), 297 (49.4%) intermediate grade (ISUP 2/3), and 86 (14.3) high grade (ISUP 4/5). Median basal circulating TT levels progressively increased as tumor grade groups increased. On multivariate models, TT, among other clinical factors, was positively associated with the risk of intermediate (OR 1.001; p = 0.023) and high tumor grades (OR 1.002, p = 0.022) compared to low-grade cancers.
CONCLUSIONS: Increased endogenous circulating basal TT levels were positively associated with ISUP tumor grade groups at the time of diagnosis indicating a close association with tumor biology. Basal TT levels may reflect the heterogeneity of the cancer population.
© 2019 S. Karger AG, Basel.

Entities:  

Keywords:  Prostate cancer; Total testosterone; Tumor grade; Tumor grade group

Mesh:

Substances:

Year:  2019        PMID: 31163438     DOI: 10.1159/000500960

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  4 in total

1.  Total testosterone density predicts high tumor load and disease reclassification of prostate cancer: results in 144 low-risk patients who underwent radical prostatectomy.

Authors:  Antonio B Porcaro; Alessandro Tafuri; Marco Sebben; Tania Processali; Marco Pirozzi; Aliasger Shakir; Nelia Amigoni; Riccardo Rizzetto; Matteo Brunelli; Filippo Migliorini; Salvatore Siracusano; Walter Artibani
Journal:  Int Urol Nephrol       Date:  2019-08-23       Impact factor: 2.370

2.  Endogenous testosterone as a predictor of prostate growing disorders in the aging male.

Authors:  Antonio Benito Porcaro; Nelia Amigoni; Alessandro Tafuri; Riccardo Rizzetto; Aliasger Shakir; Leone Tiso; Clara Cerrato; Vincenzo Lacola; Stefano Zecchini Antoniolli; Alessandra Gozzo; Katia Odorizzi; Matteo Brunelli; Filippo Migliorini; Walter Artibani; Maria Angela Cerruto; Salvatore Siracusano; Alessandro Antonelli
Journal:  Int Urol Nephrol       Date:  2021-01-03       Impact factor: 2.370

3.  Basal total testosterone serum levels predict biopsy and pathological ISUP grade group in a large cohort of Caucasian prostate cancer patients who underwent radical prostatectomy.

Authors:  Alessandro Tafuri; Marco Sebben; Riccardo Rizzetto; Nelia Amigoni; Aliasger Shakir; Tania Processali; Marco Pirozzi; Alessandra Gozzo; Katia Odorizzi; Mario De Michele; Sebastian Gallina; Alberto Bianchi; Paola Irene Ornaghi; Matteo Brunelli; Filippo Migliorini; Maria Angela Cerruto; Salvatore Siracusano; Walter Artibani; Alessandro Antonelli; Antonio B Porcaro
Journal:  Ther Adv Urol       Date:  2020-06-24

4.  Low endogenous testosterone levels are associated with the extend of lymphnodal invasion at radical prostatectomy and extended pelvic lymph node dissection.

Authors:  Antonio Benito Porcaro; Clara Cerrato; Alessandro Tafuri; Alberto Bianchi; Sebastian Gallina; Rossella Orlando; Nelia Amigoni; Riccardo Rizzetto; Alessandra Gozzo; Filippo Migliorini; Stefano Zecchini Antoniolli; Carmelo Monaco; Matteo Brunelli; Maria Angela Cerruto; Alessandro Antonelli
Journal:  Int Urol Nephrol       Date:  2021-07-06       Impact factor: 2.370

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.